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Abstract
Background: Comorbidity has a well documented detrimental effect on cancer survival. However
it is difficult to disentangle the direct effects of comorbidity on survival from indirect effects via the
influence of comorbidity on treatment choice. This study aimed to assess the impact of comorbidity
on colon cancer patient survival, the effect of comorbidity on treatment choices for these patients,
and the impact of this on survival among those with comorbidity.
Methods: This retrospective cohort study reviewed 589 New Zealanders diagnosed with colon
cancer in 1996–2003, followed until the end of 2005. Clinical and outcome data were obtained
from clinical records and the national mortality database. Cox proportional hazards and logistic
regression models were used to assess the impact of comorbidity on cancer specific and all-cause
survival, the effect of comorbidity on chemotherapy recommendations for stage III patients, and
the impact of this on survival among those with comorbidity.
Results: After adjusting for age, sex, ethnicity, area deprivation, smoking, stage, grade and site of
disease, higher Charlson comorbidity score was associated with poorer all-cause survival (HR =
2.63 95%CI:1.82–3.81 for Charlson score ≥ 3 compared with 0). Comorbidity count and several
individual conditions were significantly related to poorer all-cause survival. A similar, but less
marked effect was seen for cancer specific survival. Among patients with stage III colon cancer,
those with a Charlson score ≥ 3 compared with 0 were less likely to be offered chemotherapy (19%
compared with 84%) despite such therapy being associated with around a 60% reduction in excess
mortality for both all-cause and cancer specific survival in these patients.
Conclusion: Comorbidity impacts on colon cancer survival thorough both physiological burden
of disease and its impact on treatment choices. Some patients with comorbidity may forego
chemotherapy unnecessarily, increasing avoidable cancer mortality.
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Background
Comorbidity is the co-existence of diseases or disorders in
addition to a primary disease of interest. Comorbidity has
a detrimental effect on cancer survival, and its effect varies
by cancer site [1-10]. Colon cancer is a disease of older
people, many of whom have concomitant medical condi-
tions at diagnosis. A number of studies have suggested
that high levels of comorbidity are associated with poorer
survival among colon cancer patients [1,3,4,11-15]. How-
ever, most of these studies have not disentangled the
direct effect of comorbidity on survival, with the potential
indirect impact of comorbidity on treatment choice
which, in turn, may impact survival. These studies have
also tended to have an exclusive focus on all-cause sur-
vival, reliance on administrative data and/or have used
only one method to measure comorbidity.
Understanding the role of comorbidity in cancer survival
helps clinicians assess an individual's prognosis and pro-
vides researchers with tools to allow them to stratify or
adjust groups of patients according to risk in the same way
they do for demographic and disease factors such as age
and tumour stage [2]. Measuring comorbidity is not
straight forward and a variety of approaches have been
used including counts of conditions, comorbidity indices,
and analysis of specific conditions [2,6-8,15-20]. Simple
counts are problematic because they take no account of
the seriousness of different underlying conditions.
Comorbidity indices attempt to address this in various
ways by combining both the number and seriousness of
concomitant conditions into a single numeric score. This
approach still has limitations however, since different
conditions and combinations of conditions impact out-
comes differently depending on both the primary condi-
tion of interest (e.g. breast cancer versus lung cancer) and
the outcome being measured (e.g. mortality versus inpa-
tient costs). Using individual conditions is also problem-
atic because of the potentially large number of variables
that need to be included in the analysis and the lack of an
overall global measure of comorbidity.
It is well established that treatment with adjuvant chemo-
therapy after resection of stage III colon cancer improves
survival [21-24]. There is also good evidence that the ben-
efits of adjuvant therapy do not diminish with increasing
age [22,25-28]. Yet older people and those with comor-
bidity are less likely to receive optimum adjuvant treat-
ment for cancer [7,11,25,27,29-32]. This may be because
clinicians are concerned that advanced age and concomi-
tant conditions may increase the toxicity and side effects
of treatment, that treatments may be less effective in these
groups, or that the life expectancy of these patients is
insufficient to justify the use of potentially toxic agents
[11,25,27,33,34]. It is also possible that these patients
themselves are more likely to decline treatment [33-35].
This study investigates the impact of comorbidity on both
cancer specific and all-cause survival among colon cancer
patients using detailed comorbidity data extracted from
clinical notes. We assessed three different measures of
comorbidity – comorbidity count, the Charlson Index
[18] and individual conditions – in terms of how well
they predict cancer specific and overall survival. Finally,
we assessed the extent to which comorbidity-related dif-
ferences in survival are mediated by different treatment
options by assessing how comorbidity affects the offer of
adjuvant chemotherapy among those with stage III colon
cancer, and the extent to which the offer of chemotherapy
affects cancer specific and overall survival.
Methods
New Zealand residents diagnosed with colon cancer
between 1996 and 2003 were eligible for study inclusion.
Cases came from patients notified to the New Zealand
Cancer Registry with a primary tumour in the colon (ICD-
10-AM site codes C18-C19 excluding 18.1) and morphol-
ogy consistent with adenocarcinoma. (New Zealand has
mandatory registration of all primary cancers except non-
melanoma skin cancers and carcinoma-in-situ.) Patients
were ineligible if they were less than 25 years at diagnosis,
were normally resident outside New Zealand, had a previ-
ous diagnosis of colon cancer, or were diagnosed after
death. All Ma ¯ori patients meeting the above criteria were
included along with an approximately equal number of
randomly-sampled non-Ma ¯ori patients. This random
sample was identified by assigning a unique random six-
digit number to all non-Ma ¯ori cases, placing these in
numerical order and selecting the first four hundred (the
approximate size of the Ma ¯ori cohort). This sampling
frame allowed an assessment of survival disparities
between Ma ¯ori and non-Ma ¯ori patients with colon cancer
(data presented elsewhere)[36].
Clinical data were abstracted from patients' clinical
records from both public and private health care provid-
ers. Data were collected on all major comorbid conditions
present at the time of diagnosis and all conditions
included in the Charlson comorbidity index. The Charl-
son index was developed in 1987 using data from a cohort
of 607 medical patients, and validated with a population
of breast cancer patients. Nineteen conditions are allo-
cated a weight of 1 to 6 depending on the adjusted relative
risk of 1-year mortality, and summed to give an overall
score [18]. The higher the individual's score, the higher
the level of comorbidity. Additional conditions included
in the comorbidity count were angina, hypertension, car-
diac arrhythmias, previous pulmonary embolism, cardiac
valve disease, inflammatory bowel disease, other neuro-
logical conditions (including multiple sclerosis, Parkin-
son's disease, epilepsy) and major psychiatric conditionsBMC Cancer 2009, 9:116 http://www.biomedcentral.com/1471-2407/9/116
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(including schizophrenia, bipolar disease and depressive
psychosis).
Pathology reports were obtained for all patients from their
clinical records, the Cancer Registry or directly from the
reporting laboratory. Data were recorded on a standard-
ised form by a physician (SH) and double-entered into an
electronic database. Data included patients' details (age,
sex, ethnicity and small area deprivation), tumour charac-
teristics (including location, histological features and
stage at diagnosis), smoking status and treatment factors
(such as receipt of surgery and chemotherapy offered).
Small area deprivation was defined by the NZ Deprivation
Index, an ecological measure based on a combination of
nine socioeconomic variables derived from the national
census (i.e. housing tenure, benefit receipt, unemploy-
ment, income, telephone access, car access, single parent
families, education and household crowding). This was
assigned according to each patient's domicile (census
area) code at the time of diagnosis [37]. Stage was based
on TNM staging groups [38].
Outcome data (vital status and cause of death) were
obtained by linking study patients to the New Zealand
national mortality database, with follow-up to the end of
2005. Patients whose deaths were not recorded in the
mortality database were assumed to be still alive at the
end of follow-up. For cancer specific analyses, patients
who died from causes other than colon cancer were cen-
sored at the date of death.
Comorbidities were classed in three different ways: i) The
total number of comorbid conditions ('comorbidity
count') was summed for each patient and categorised into
four groups 0, 1, 2 or 3+ conditions; ii) Charlson comor-
bidity scores were categorised into 0, 1–2 or 3+; and iii)
Specific comorbid conditions were individually catego-
rised.
Cox proportional hazards modelling was used to calculate
hazard ratios (HRs) for cancer specific and all-cause mor-
tality. Crude and adjusted HRs were compared for each of
the three approaches to classifying comorbidity (i.e.
comorbidity count, Charlson comorbidity index and spe-
cific conditions) to see how well each approach predicted
survival. Hazard ratios were first adjusted for patient fac-
tors (age, sex, ethnicity, year of cancer registration, depri-
vation, smoking) and then adjusted for patient factors and
disease factors (stage, grade and site of cancer).
To assess how well the three different measures of comor-
bidity predicted cancer specific and all-cause survival, the
fit of a baseline model including patient and disease fac-
tors was compared to models that included each of the
three approaches in turn using the likelihood ratio test.
Individual conditions were included in the models in two
ways; firstly by including only conditions with predictive
HR of 1.2 or more, and secondly by including all individ-
ual conditions.
Adjuvant chemotherapy was recommended for use in
patients with stage III colon cancer throughout the period
of the study [39]. Logistic regression restricted to patients
with stage III cancer was used to assess the relative odds of
those with and without comorbidity being offered such
therapy. Cox regression modelling was used to assess the
impact on survival of the offer of chemotherapy after
adjusting for age, sex, ethnicity and comorbidity.
All analyses were carried out in STATA (version 10) [40].
Approval for this study was granted by the New Zealand
Multi-Region Ethics Committee.
Results
A total of 776 patients met the study criteria based on
Cancer Registry records. Ninety one (12%) of those sam-
pled were later excluded because further information
showed they were ineligible for study inclusion (65 had
miscoded data (primarily cancer site) in the Cancer Regis-
try and a further 26 had no histological diagnosis), giving
685 patients in total. Full data were obtained for 589
(86.0% of the eligible sample). During the follow up
period 227 patients were identified as dying from colon
cancer and 89 from other causes.
As expected, most colon cancer patients were aged over 55
years and were more likely to live in more deprived areas
in New Zealand, consistent with the age structure of this
cohort. Just under half the cohort was Maori, in keeping
with the original sampling strategy. A fifth were current
smokers, and a further 39% were ex-smokers. The disease
related factors (stage, grade and site) were reasonably con-
sistent with the largely unscreened population in New
Zealand (Table 1). All patients received standard surgical
treatment (tumour resection) except a small proportion
(6%) who died before surgery or had clinically advanced
disease for which surgery was not indicated.
Seventy percent of patients had at least one comorbid con-
dition and a quarter had three or more (Table 1). The
most common conditions were hypertension (38.0%),
chronic respiratory disease (21.9%), and diabetes
(16.1%). Nearly half (48.2%) of the patients had a Charl-
son score of zero, 40.8% scored 1–2 and the remaining
11.0% scored 3 or more.
Table 2 shows hazard ratios firstly for cancer specific then
for all-cause mortality for the three different measures of
comorbidity. In the fully adjusted models, hazard ratios
increased with increasing levels of both the comorbidityBMC Cancer 2009, 9:116 http://www.biomedcentral.com/1471-2407/9/116
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Table 1: Characteristics of cohort participants
Patient factors n%
Sex Male 305 51.8
Female 284 48.2
Age 25–54 yrs 98 16.6
55–64 yrs 154 26.2
65–74 yrs 186 31.6
75+ yrs 151 25.6
Ethnicity* Maori 285 51.6
Non-Maori 304 48.4
NZDep 1–2 59 10.0
3–4 79 13.4
5–6 111 18.9
7–8 159 27.0
9–10 181 30.7
Smoking Non-smoker 234 39.7
Ex-smoker 232 39.4
Smoker 123 20.9
Disease factors n%
Stage I 76 12.9
II 183 31.1
III 190 32.3
IV 140 23.8
Grade Well-differentiated 57 9.7
Moderately 424 72.0
Poorly 108 18.3
Site Right 239 40.6
Left 220 37.4
Rectosigmoid 99 16.8
Synchronous 31 5.3
Comorbidities n%
Angina 72 12.2
Hypertension 224 38.0
Previous MI 49 8.3
Cardiac arrhythmias 79 13.4
CHF 62 10.5
PVD 24 4.1
Chronic respiratory disease 129 21.9
GI ulcer disease 24 4.1
Other cancer 27 4.6
Cerebrovasc disease 41 7.0
Diabetes (all) 95 16.1
Renal disease (all) 31 5.3
Other neurological 39 6.6
Charlson comorbidity index score O 284 48.2
1–2 240 40.8
3+ 65 11.0
Number of conditions** 0 181 30.7BMC Cancer 2009, 9:116 http://www.biomedcentral.com/1471-2407/9/116
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count and the Charlson comorbidity index. For individual
comorbid conditions, congestive heart failure and diagno-
sis of a non-cerebrovascular neurological condition were
significantly related to worse colon cancer specific survival
after adjustment for patient and disease factors (HR =
1.83, 95% CI 1.14–2.93 and 1.96 95% CI 1.12–3.42
respectively). A history of previous myocardial infarction,
chronic respiratory disease, cerebrovascular disease, dia-
betes, and chronic renal disease also appeared to predict
worse survival (HR>1.2), but did not reach the level of sta-
tistical significance. In contrast, gastrointestinal ulcer dis-
ease, a history of other previous cancer, and angina
appeared to have a non-significant protective effect
although confidence intervals were wide (HR = 0.76, 95%
CI 0.31–1.87, 0.71, 95% CI 0.32–1.55 and 0.81, 95% CI
0.51–1.30 respectively).
Global measures of comorbidity were strongly associated
with poorer overall survival. In the fully adjusted models
Charlson comorbidity index scores of 1–2 and 3 or more
were associated with hazard ratios of 1.60 (95% CI 1.24–
2.07) and 2.63 (95% CI 1.82–3.81) respectively, com-
pared with a Charlson score of 0. Likewise, a greater
number of conditions were associated with poorer sur-
vival. Individual comorbid conditions showed a stronger
association with all-cause mortality than cancer specific
mortality. After adjusting for patient and disease factors,
significantly poorer survival was seen with a history of
previous myocardial infarction (HR = 1.91, 95% CI 1.31–
2.79), cardiac arrhythmias (HR = 1.48, 95% CI 1.07–
2.06), congestive heart failure (HR = 2.30, 95% CI 1.63–
3.25), peripheral vascular disease (HR = 2.02, 95% CI
1.18–3.48), diabetes (HR = 1.53, 95% CI 1.15–2.05),
chronic renal disease (HR = 1.79, 95% CI 1.12–2.86) and
diagnosis of other significant neurological conditions
(HR = 2.02, 95% CI 1.32–3.11). Chronic respiratory dis-
ease and cerebrovascular disease also appeared to be non-
significantly negatively related, and GI ulcer disease posi-
tively related to survival.
Table 3 shows the likelihood ratio test results when each
comorbidity measure was added to the survival model.
For the cancer specific mortality risk, adding either the
Charlson index or the comorbidity count to the baseline
Cox regression model did not significantly improve
model fit over and above demographic and disease factors
(p = 0.12 and 0.57 respectively). Inclusion in the model of
individual conditions with adjusted hazard ratios of >1.2
provided significantly better fit (LR chi2 (7) = 14.46; p =
0.04). Adjusting for comorbidity had a more marked
effect on model fit for all-cause mortality hazard with
inclusion of any of the three measures of comorbidity
resulting in highly significant improvement in model fit
compared with the baseline model.
To ascertain whether the survival disadvantage of patients
with higher comorbidity was related to different treatment
choices we investigated whether comorbidity was associ-
ated with different levels of chemotherapy use, and
whether that in turn was related to poorer survival among
those with comorbidity. The Charlson Index was used
because we required a global measure of comorbidity for
this analysis. There were 190 patients with stage III disease
in our cohort, 129 (68%) of whom were offered chemo-
therapy. Table 4 shows the proportions of patients with
stage III cancer who were offered adjuvant chemotherapy
by sex, age, ethnicity and comorbidity. Older patients and
those with higher comorbidity were considerably less
likely to be offered chemotherapy. For example, 63% of
those aged over 75 years were not offered adjuvant ther-
apy compared with 20% of those aged 55–64 years. Like-
wise, 16% of those without any recorded comorbidity
were not offered chemotherapy, compared with 81% of
those with the highest level of comorbidity. The adjusted
odds ratios (Table 4) show that age and comorbidity were
each independently associated with a significantly
decreased likelihood of being offered chemotherapy.
Not being offered adjuvant chemotherapy was associated
with significantly poorer survival among those with stage
III disease after adjusting for age, sex and comorbidity
(HR = 2.32; 95%CI = 1.34–4.00 for cancer specific sur-
vival; and HR = 2.71; 95% CI = 1.68–4.36 for all-cause
survival). Furthermore, the survival differential for those
with the highest level of comorbidity (Charlson Index
score ≥3) compared to those with the lowest (Charlson
Index score = 0) was considerably reduced after adjusting
for whether or not they were offered adjuvant chemother-
apy. After adjustment for age and sex, those with a Charl-
son score of 3+ compared with 0 had a cancer specific HR
of 2.27 (95% CI 0.96–5.45). After adjusting for being
offered chemotherapy this HR was 1.43 (95% CI 0.57–
3.60), a 66% reduction in excess risk of death. The pattern
was similar for all-cause survival with a 59% reduction in
11 4 7 2 5 . 0
21 1 7 1 9 . 9
3+ 144 24.5
*Maori purposively oversampled
**Included all conditions included in Charlson Comorbidity Index as well as angina, hypertension, cardiac arrhythmias, previous pulmonary 
embolism, cardiac valve disease, inflammatory bowel disease, other neurological conditions (including multiple sclerosis, Parkinson's disease, 
epilepsy) and major psychiatric conditions (including schizophrenia, bipolar disease and depressive psychosis)
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Table 2: Hazard ratios for cancer specific and all cause mortality for patients with specified co-morbidities
Crude HR Adjusted for pt factors1 Adjusted for pt and disease factors2
Cancer specific mortality
Angina 0.74 0.48–1.15 0.75 0.48–1.19 0.81 0.51–1.30
Hypertension 0.97 0.74–1.27 0.96 0.72–1.28 0.92 0.69–1.23
Previous MI 1.23 0.77–1.97 1.30 0.81–2.11 1.49 0.90–2.46
Cardiac arrhythmias 0.82 0.54–1.25 0.88 0.57–1.36 1.17 0.74–1.83
CHF 1.13 0.74–1.75 1.10 0.70–1.72 1.83 1.14–2.93
PVD 0.64 0.26–1.55 0.71 0.39–1.75 1.18 0.48–2.93
Chronic respiratory disease 1.16 0.85–1.58 1.06 0.77–1.46 1.24 0.89–1.74
GI ulcer disease 0.49 0.20–1.18 0.50 0.21–1.22 0.76 0.31–1.87
Other cancer 0.77 0.36–1.63 0.79 0.37–1.71 0.71 0.32–1.55
Cerebrovasc disease 1.23 0.75–2.02 1.30 0.78–2.16 1.25 0.74–2.10
Diabetes (all) 1.18 0.84–1.68 1.14 0.79–1.63 1.27 0.88–1.84
Renal disease (all) 1.10 0.60–2.01 1.01 0.54–1.87 1.42 0.76–2.66
Other neurological 1.19 0.71–1.97 1.35 0.80–2.25 1.96 1.12–3.42
Charlson comorbidity index
O 1.00 1.00 1.00
1–2 1.26 0.96–1.66 1.22 0.91–1.64 1.32 0.98–1.77
3+ 0.86 0.52–1.42 0.88 0.53–1.47 1.48 0.88–2.50
Number of conditions*
0 1.00 1.00 1.00
1 1.30 0.93–1.80 1.29 0.92–1.83 1.06 0.76–1.55
2 1.15 0.79–1.68 1.13 0.75–1.70 1.23 0.81–1.87
3+ 1.00 0.69–1.45 1.01 0.67–1.53 1.33 0.87–2.04
All-cause mortality
Angina 0.96 0.68–1.34 0.86 0.61–1.23 0.91 0.63–1.31
Hypertension 1.03 0.82–1.29 0.93 0.73–1.19 0.90 0.70–1.15
Previous MI 1.67 1.17–2.38 1.74 1.21–2.52 1.91 1.31–2.79
Cardiac arrhythmias 1.26 0.93–1.72 1.19 0.86–1.65 1.48 1.07–2.06
CHF 1.79 1.31–2.45 1.61 1.16–2.24 2.30 1.63–3.25
PVD 1.46 0.87–2.46 1.40 0.82–2.40 2.02 1.18–3.48
Chronic respiratory disease 1.29 0.99–1.66 1.12 0.85–1.46 1.26 0.96–1.66
GI ulcer disease 0.61 0.32–1.19 0.60 0.31–1.17 0.76 0.38–1.49
Other cancer 1.31 0.79–2.16 1.25 0.74–2.10 1.16 0.68–1.98
Cerebrovasc disease 1.36 0.91–2.04 1.28 0.85–1.93 1.27 0.84–1.94
Diabetes (all) 1.48 1.12–1.95 1.44 1.08–1.92 1.53 1.15–2.05
Renal disease (all) 1.52 0.96–2.39 1.32 0.83–2.10 1.79 1.12–2.86
Other neurological 1.44 0.97–2.16 1.58 1.05–2.38 2.02 1.32–3.11
CCI
O 1.00 1.00 1.00
1–2 1.68 1.32–2.14 1.55 1.20–2.00 1.60 1.24–2.07
3+ 1.84 1.30–2.60 1.78 1.24–2.55 2.63 1.82–3.81
Number of conditions*
0 1.00 1.00 1.00
1 1.30 0.95–1.78 1.26 0.92–1.73 1.08 0.78–1.49
2 1.50 1.08–2.08 1.40 0.98–1.99 1.45 1.01–2.07
3+ 1.73 1.28–2.35 1.63 1.17–2.28 2.00 1.41–2.82
1 includes age, sex, ethnicity, NZdep, year of registration, smoking
2 includes age, sex, ethnicity, NZdep, year of registration, smoking, stage, grade and site of cancer
* Included all conditions included in Charlson Comorbidity Index as well as angina, hypertension, cardiac arrhythmias, previous pulmonary 
embolism, cardiac valve disease, inflammatory bowel disease, other neurological conditions (including multiple sclerosis, Parkinson's disease, 
epilepsy) and major psychiatric conditions (including schizophrenia, bipolar disease and depressive psychosis)BMC Cancer 2009, 9:116 http://www.biomedcentral.com/1471-2407/9/116
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excess risk of death (HR = 3.56, 95% CI 1.80–7.05 to HR
= 2.06, 95% CI 0.99–4.30).
Discussion
We found that comorbidity was very common among this
nationally representative cohort of patients with colon
cancer. Seven out of ten patients had at least one recorded
comorbid condition, and comorbidity had a substantial
negative impact on both cancer specific and all-cause sur-
vival. This impact varied both between different comorbid
conditions, and between the two measures of survival
used. We found that multivariable models of survival that
included specific conditions known to increase mortality
hazard by 20% or more had better fit than models using
comorbidity count, Charlson index or all comorbid con-
ditions. This effect was particularly pronounced for cancer
specific survival. We found that patients with stage III
colon cancer who had higher levels of comorbidity or who
were older were considerably less likely to be offered adju-
vant chemotherapy, despite our finding that being offered
chemotherapy improved cancer specific and all-cause sur-
vival in these patients.
Our findings are consistent with other work in this area
showing that comorbidity is common among people with
colon cancer and that it has a substantial impact on sur-
vival [2-4,12,15,41-45]. A number of studies have found
an association between the Charlson index and survival
among colon cancer patients [4,12,14,44,46]. The Charl-
son index is a well established tool for summarising
comorbidity; however there are problems with its use. It
includes some conditions that have not been shown to
have an impact on survival among patients with colon
cancer (e.g. peptic ulcer disease), it may exclude some that
do have such an impact (e.g. non-cerebrovascular neuro-
logical conditions), and it assumes that the impact of mul-
tiple conditions is additive on a relative scale. In fact,
Gross et al (2006)[1] found the effects of combinations of
Table 3: Results of likelihood ratio test; baseline model as comparison: cancer specific mortality and all-cause mortality
Cancer specific mortality All-cause mortality
Model 1 (baseline + Charlson categories) LR chi2(2) = 4.28 P = 0.12 LR chi2(2) = 27.56 P < 0.0001
Model 2 (baseline + comorbidity count) LR chi2(3) = 2.03 P = 0.57 LR chi2(3) = 18.60 P = 0.0003
Model 3 (baseline + conditions with independent* HR≥1.2)1 LR chi2(7) = 14.46 P = 0.04 LR chi2(9) = 46.23 P < 0.0001
Model 4 (baseline + all conditions with 20 or more cases) LR chi2(13) = 19.93 P = 0.10 LR chi2(13) = 52.66 P < 0.0001
Baseline model adjusts for following covariates: Age, sex, ethnicity, NZdep, smoking, year of registration, stage, grade and site.
*after adjustment for patient and colon cancer related factors
1For cancer specific mortality this included previous myocardial infarction, congestive heart failure, cerebrovascular disease, other neurological 
conditions, diabetes, renal disease, chronic respiratory disease. For all cause mortality this included all these conditions and also cardiac 
arrhythmias, and peripheral vascular disease.
Table 4: Proportion and odds ratios of patients with stage III colon cancer not offered chemotherapy
total (n, %) not offered 
chemo
Crude odds ratio 95% confidence 
intervals
Adjusted odds 
ratio*
95% confidence 
intervals
Sex Female 103 (29, 28%) 1.0 1.0
Male 86 (31, 36%) 1.4 0.8–2.7 1.8 0.9–3.9
Age 25–54 yrs 33 (4, 12%) 1.0 1.0
55–64 yrs 50 (10, 20%) 1.8 0.5–6.4 1.4 0.4–5.1
65–74 yrs 55 (14, 26%) 2.5 0.7–8.3 1.2 0.3–4.5
75+ yrs 51 (32, 63%) 12.2 3.7–40.1 8.7 2.3–32.4
Ethnicity Non-Maori 105 (31, 30%) 1.0 1.0
Maori 84 (29, 35%) 1.3 0.7–2.3 1.5 0.7–3.4
Charlson 
comorbidity index
O 97 (15, 16%) 1.0 1.0
1–2 76 (32, 42%) 4.0 2.0–8.1 3.2 1.4–7.1
3+ 16 (13, 81%) 23.7 6.0–93.3 20.1 4.2–95.6
*adjusted for all listed variablesBMC Cancer 2009, 9:116 http://www.biomedcentral.com/1471-2407/9/116
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comorbidities on survival among colon cancer patients
were complex and difficult to predict. For example, diabe-
tes, CHF and chronic respiratory disease all exerted strong
independent effects on survival. Patients with both CHF
and diabetes had considerably worse survival than those
with either condition individually; whereas those with
chronic respiratory disease had similar survival rates
whether they also had diabetes or not. Consistent with
this, we found that inclusion of specific conditions within
multivariable models provided better model fit than
either a simple comorbidity count or Charlson comorbid-
ity index, and were therefore more likely to adequately
adjust for the effect of comorbidity on cancer survival.
Baldwin et al (2006) compared four administrative
claims-based measures of comorbidity and concluded
that while none was clearly superior, the Elixhauser meas-
ure, which is based on individual conditions, was possibly
best at predicting chemotherapy receipt and non-cancer
death[15] Assessing the impact of individual conditions
on survival may also be more useful to clinicians in terms
of assessing the prognosis of particular patients. However,
there are clearly situations where a single summarised
measure of comorbidity is required, either because study
numbers are not sufficiently large to include individual
conditions in analyses, or because the impact of a global
measure of comorbidity is of interest, for example, when
trying to assess the independent effect of comorbidities
adjusting for other covariates.
It is not entirely clear the extent to which comorbidity acts
on survival directly or through its impact on treatment
choice or effectiveness. Intuitively it is likely that both
play a part. We found clinicians were less likely to offer
chemotherapy to patients with higher levels of comorbid-
ity and older patients consistent with evidence from other
studies [11,15,25,27,32,46]. There are a number of possi-
ble explanations for this pattern including physicians'
concern regarding the potential for increased toxicity of
treatment among these groups, concern that these
patients may have a short remaining life expectancy limit-
ing the benefit of adjuvant therapy or concern that these
treatments may be less effective in elderly or sicker
patients. In fact, there is good evidence that these treat-
ments are both well tolerated and effective even in very
elderly patients, and that elderly patients are as likely to
choose chemotherapy as younger ones [26-28,33,35].
There is less evidence relating to these factors in patients
with multiple comorbidity. However, the few available
studies suggest that chemotherapy has a positive effect on
survival among patients with stage III colon cancer even
among those with high comorbidity [1,46]. We also
found being offered chemotherapy was associated with a
reduction in excess mortality risk of around 60% for both
cancer specific and all-cause mortality among those with
highest levels of comorbidity. This again supports the idea
that at least part of the survival disparity between those
with and without comorbidity is mediated through differ-
ences in treatments offered [7]. It is important to note that
our analyses are based on observational data, not ran-
domised trial. Therefore, it is likely that the variable 'being
offered chemotherapy' may be acting as a surrogate for
other prognostic factors on which we did not have data
such as functional status. This means that the reduction in
mortality associated with the offer of chemotherapy may
be somewhat lower in reality than the 60% observed in
this study.
Potential limitations of our study include limited power
and retrospective ascertainment of comorbidity. Our sam-
ple was too small to assess the impact of rarer conditions
on survival, or to assess the impact of multiple combina-
tions of specific conditions. Also, given that this was retro-
spective, observational data, conditions were only
included if they had been diagnosed by a physician at the
time of diagnosis. This may have led to some misclassifi-
cation in those with undiagnosed disease, which would
most likely dilute the apparent effect of comorbidity on
survival.
A principal strength of our study is the presence of
detailed comorbidity data based on clinical records rather
than administrative data. Comorbidity data were
extracted from clinical notes by a study physician, allow-
ing comprehensive assessment and classification of
patient comorbidity without restriction to pre-defined cat-
egories. Comorbidity data from medical notes have sev-
eral advantages over data obtained from administrative
sources in which there tends to be under ascertainment of
some conditions and there can be difficulty differentiating
complications of treatment from pre-existing conditions
[2,16,47]. Also, because we had access to clinical notes, we
were able to ascertain the proportion of Stage III patients
who were offered chemotherapy, rather than those who
received it. The offer of chemotherapy is important in
identifying the clinical decisions and preferences of physi-
cians. Full data were obtained for a high proportion of our
cohort (86.0% of eligible cases).
Conclusion
Comorbidity is an important factor in the assessment of
mortality risk for patients with colon cancer. The measure-
ment and application of comorbidity in studies of cancer
survival remains problematic. Based on our findings we
recommend using data on individual conditions where
possible in models that aim to adjust for comorbidity as a
confounder or to assess its role as a mediating influence in
survival. However in studies where comorbidity is a pri-
mary exposure or outcome of interest it may still be nec-
essary to use global measures of comorbidity such as
comorbidity count or a weighted index. Our findings alsoBMC Cancer 2009, 9:116 http://www.biomedcentral.com/1471-2407/9/116
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support the idea that the poorer prognosis of those with
high comorbidity levels is at least partially mediated by
less active treatment in these patients. We found clear evi-
dence that chemotherapy has a positive impact on sur-
vival among stage III patients, even in those with the
highest levels of comorbidity. Cancer treatment guide-
lines should ensure patients are offered all appropriate
treatment and that chemotherapy is not withheld unnec-
essarily in older patients or those with higher comorbid-
ity. Further research would be useful to identify which
patients with comorbidity are most likely to benefit from
additional treatment, and what criteria should be used to
decide whether adjuvant treatment should be appropri-
ately withheld.
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